A company dedicated
to animal health
At the beginning of October the GMBO (Global Marketing) organized the first Virbac Dairy Symposium in France, attended by experts from the dairy sector and Virbac staff from all over the world. Fabrice Payot, Global Marketing manager on the dairy cattle segment, explains the objectives of this major event.
Virbac United States inaugurates the April 20th, 2014 a new building for its R&D activities. With which objectives? The answers from R&D vice-president of the American subsidiary.
Dec 15 - Development of new monoclonal antibody-based veterinary medicines: Virbac announces the signature of a collaboration agreement with Nexvet
As the world's 5th largest manufacturer in the companion animal market, a major part of Virbac's Research & Development investment is made in this field. In this context, the Group is pleased to announce the signature of a ten-year collaboration agreement with biopharmaceutical company Nexvet. The aim of this agreement is for Virbac to provide input to Nexvet’s development of new monoclonal antibody-based veterinary medicines and to market these medicines, if approved by regulators, outside the USA and Canada.
Customer driven innovation
Financial public releases
Sustained growth in the fourth quarter
Jan 05 - Virbac announces the closing of the SENTINEL® brands family acquisition in the United States
Virbac announces the successful closing on January 2nd of its agreement with Eli Lilly and Company to acquire two major parasiticides for dogs in the United States: SENTINEL® Flavor Tabs® and SENTINEL® SPECTRUM®, marketed up to now by Novartis Animal Health.
Virbac announces that it has entered into an agreement with Eli Lilly and Company to acquire major United States veterinary products currently marketed by Novartis Animal Health. Eli Lilly has agreed to divest these U.S. assets in connection with the U.S. Federal Trade Commission’s review of Eli Lilly’s pending acquisition of Novartis Animal Health worldwide.